Maxpro Capital Acquisition Corp. (JMAC) to Combine with Apollomics
Maxpro Capital (NASDAQ:JMAC) has entered into a definitive agreement to combine with biopharmaceutical firm Apollomics at a pre-money equity value of $899 million. Foster City, California-based is developing a line of drug candidates to treat rare cancers with clinical processes nearing completion in both the US and Chinese treatment markets. The combined company is expectedRead More
To access this post, you must purchase 1 - User: Monthly Plan.